CellaVision AB (publ)

Stockholm Stock Exchange:CEVI.ST

Sector

🏥 Health Care

Industries

💻 Telehealth

🔬 Clinical Trials

💼 Enterprise Resource Planning (ERP)

🩺 Medical Instruments

🌐 Software-as-a-Service (SaaS)

Location

Sweden

Market Cap

USD 453.80 M

Share Price

USD 19.03

Avg Daily Volume

26,505

Change (1 day)

1.31%

Change (1 year)

-18.62%

Change (YTD)

-3.13%

CellaVision AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2024: USD -8.56 M

CellaVision AB (publ) Net Cash Used Provided By Financing Activities is USD -8.56 M for the year ending December 31, 2024, a -10.64% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

CellaVision AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2023 was USD -9.58 M, a 10.93% change year over year.
CellaVision AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -8.63 M, a 61.78% change year over year.
CellaVision AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD -5.34 M, a 25.04% change year over year.
CellaVision AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD -4.27 M, a -154.97% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Net Cash Used Provided By Financing Activities	Depreciation And Amortization	Dividends Paid	Common Stock Issued

Stockholm Stock Exchange: CEVI.ST

CellaVision AB (publ)

CEO	Mr. Simon Ostergaard Ph.D.
IPO Date	May 28, 2007
Location	Sweden
Headquarters	Mobilvägen 12
Employees	228
Sector	🏥 Health Care
Industries Telehealth 🔬 Clinical Trials 💼 Enterprise Resource Planning (ERP) 🩺 Medical Instruments 🌐 Software-as-a-Service (SaaS)

Description

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.